Showing results (1421-1430 of 2,107) with videos related to
Sort By:
Pageof 211
CNS Drugs|May 19, 2026
Opioid Use Disorder Treatment Gaps and Emerging Therapeutics to Address ThemMatthew L BanksCNS Drugs|May 14, 2004
Spotlight on the pharmacoeconomics of escitalopram in depressionKatherine F Croom, Greg L PloskerCNS Drugs|December 9, 2004
The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disordersAmy Cameron Ellis, Jeffrey RosenfeldCNS Drugs|May 24, 2005
Post-traumatic stress disorder in women: epidemiological and treatment issuesSoraya Seedat, Dan J Stein, Paul D CareyCNS Drugs|May 16, 2026
Enhancing Drug Response Prediction in Epilepsy with Emerging Multimodal Models: Focus on Clinical, Pharmacologic, and Genomic FactorsAlison Anderson, Richard Shek-Kwan Chang, Mark Howard, et al.CNS Drugs|February 18, 2026
Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1)Ignacio Bejarano, Silvia Jiménez-Jorge, María Ángeles Lobo-Acosta, et al.CNS Drugs|September 25, 2013
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approachLeslie CitromeCNS Drugs|November 10, 2016
Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current StatusTara Swart, Michael J HurleyCNS Drugs|February 6, 2014
Combined pharmacotherapies for the management of alcoholism: rationale and evidence to dateMary R Lee, Lorenzo LeggioCNS Drugs|March 29, 2014
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive reviewJ Peuskens, L Pani, J Detraux, et al.Pageof 211